Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Helminth beta-tubulin is a vital structural protein found in parasitic worms, including nematodes, cestodes, and trematodes. It functions by forming heterodimers with alpha-tubulin to assemble microtubules, which are essential cytoskeletal components involved in cell division, intracellular transport, and the maintenance of cellular architecture [1, 3]. This protein serves as the primary therapeutic target for the benzimidazole class of broad-spectrum anthelmintic drugs, such as albendazole and mebendazole [1, 4]. These compounds bind specifically to helminth beta-tubulin, inhibiting microtubule polymerization and causing lethal disruption to the parasite's physiological processes [1, 12]. A significant challenge in the clinical use of these drugs is the development of resistance, which is frequently associated with single nucleotide polymorphisms (SNPs) at specific amino acid residues, notably codons 167, 198, and 200 [5, 16]. These mutations reduce the binding affinity of the drugs to the tubulin molecule, necessitating the ongoing surveillance of resistance markers and the development of novel antiparasitic strategies [3, 7].
Benzimidazole drugs bind to the colchicine-binding site of helminth beta-tubulin, inhibiting its polymerization into microtubules. This disruption of microtubule dynamics arrests essential cellular processes such as mitosis and intracellular transport, leading to the depletion of energy reserves (e.g., glucose uptake inhibition) and the eventual death of the parasite [1, 2, 10].
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Helminth beta-tubulin (TUBB).